Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-pharmacology trial of a pneumococcal vaccine inducing anti-oxidized LDL antibodies
2015-005650-35Phase 2Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Apr 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of Prevnar 13 in atherosclerosis (2 arms), sponsored by Centre for Human Drug Research. Primary endpoint: Anti-oxidized LDL IgM antibody titer. Started Apr 2016; status: completed.
02
Drugs
Prevnar 13
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on 2015-005650-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005650-35.